Post-ASH 2022 Lymphoma & CLL

19 January 2023 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in lymphoma and chronic lymphocytic leukemia (CLL) from ASH 2022

The Post-ASH 2022 Lymphoma & CLL Virtual Workshop took place on 19 January 2022, and featured a series of short presentations from invited experts on selected abstracts from the 64th ASH Annual Meeting with interactive panel discussions after each session.

Addressing unmet needs in lymphoma Mantle cell lymphoma Advances in CLL, SLL and Richter's transformation Key updates for CAR-T in lymphoma Treatment updates for DLBCL

Session 1: addressing unmet needs in lymphoma

Phase I/II study of subcutaneous epcoritamab with R2 in 1L FL

Lorenzo Falchi Memorial Sloan Kettering Cancer Center, New York City, NY, United States

AFM13 plus cord blood-derived NK cells in double-refractory CD30+ lymphoma

Yago Nieto The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Iberdomide alone or with anti-CD20 antibody in R/R lymphoma

Catherine Thieblemont Saint-Louis Hospital, Paris, France

Session 1 panel discussion

Session 2: mantle cell lymphoma

Phase II study of ALR with real-time monitoring of MRD in 1L MCL

Bijal Shah H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Tarmac study: time-limited ibrutinib and tisa-cel in R/R MCL

Adrian Minson Peter MacCallum Cancer Centre, Melbourne, Australia

Tandem study: bispecific LV20.19 CAR-Ts for MCL

Nirav Niranjan Shah Medical College of Wisconsin, Milwaukee, WI, United States

Session 2 panel discussion

Session 3: advances in CLL, SLL and Richter’s transformation

ALPINE study: zanubrutinib vs ibrutinib for R/R CLL/SLL

Jennifer Brown Dana-Farber Cancer Institute, Boston, MA, United States

FLAIR study: ibrutinib + venetoclax with MRD-driven treatment duration in CLL

Talha Munir Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

BRUIN study: pirtobrutinib in Richter's transformation

Nirav Niranjan Shah Medical College of Wisconsin, Milwaukee, WI, United States

EPCORE CLL-1 study: subcutaneous epcoritamab in Richter's syndrome

Arnon Kater University of Amsterdam, Amsterdam, Netherlands

Session 3 panel discussion

Session 4: key updates for CAR-T in lymphoma

Survival outcomes with CD19 CAR-T therapy in DHL and DEL

Joanna Zurko Medical College of Wisconsin, Milwaukee, WI, United States

Targeting CNS lymphoma with intravenous axi-cel

Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States

Alycante study: axi-cel as 2L therapy in transplant-ineligible lymphoma

Roch Houot Rennes University Hospital, Rennes, France

Pilot study of axi-cel for R/R primary and secondary CNS lymphoma

Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States

Transform study: liso-cel vs SOC in 2L for R/R LBCL

Manali Kamdar University of Colorado Cancer Center, Denver, CO, United States

Session 4 panel discussion

Session 5: treatment updates for DLBCL

Phase I study of rapcabtagene autoleucel in R/R LBCL

Pere Barba Vall d’Hebron University Hospital, Barcelona, Spain

ELM-2 study: odronextamab in R/R DLBCL

Won-Seog Kim Samsung Medical Center, Seoul, Korea, Republic of

Session 5 panel discussion

The continued success of the post-ASH meetings is in no small part due to the ongoing funding of supporters, allowing unique opportunities for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes.
For more information about supporting future meetings and activities, please contact us here.

For the latest updates in Lymphoma and CLL, visit The Lymphoma Channel and The CLL Channel

Post-ASH 2022 Lymphoma & CLL

Post-ASH 2022 Lymphoma & CLL

Session 1: addressing unmet needs in lymphoma

Session 2: mantle cell lymphoma

Session 3: advances in CLL, SLL and Richter’s transformation

Session 4: key updates for CAR-T in lymphoma

Session 5: treatment updates for DLBCL

Sign-up for our Newsletter!